Feature

Research Reports

Resource Utilization and Expenditures During the “Watchful Waiting” Period in Patients With Recurrent Ovarian Cancer

02/19/2019

Brooke Harrow, PhD

Karin Travers, DSc

Brian M Davis, PhD

Paula Smith, MS

Adrienne M Gilligan, PhD

Paul Juneau, MS

Mohan Bala, PhD

Abstract: This article aims to quantify the use of health services during the watchful waiting period after second-line platinum-based therapy among patients with ovarian cancer. Women newly diagnosed with ovarian,...

...

02/19/2019

Journal of Clinical Pathways

Perspectives

Getting “Bundle Ready”: How Provider Organizations Can Design Clinical Pathways in the Context of Bundled Payments

02/19/2019

Joshua M Liao, MD, MSc, FACP

Christopher Chen, MD, MBA

Abstract: Clinical pathways can be meaningful tools for improving the quality and value of care. Pathway initiatives are also influenced by payment policy, taking different forms and adopting different emphases...

...

02/19/2019

Journal of Clinical Pathways

Research Reports

The Oncology Care Model Performance Period 2 Results: Practices Are Making Some Progress, But Major Challenges Remain

12/13/2018

Charles Saunders, MD

Abstract: When launched in 2016, the Oncology Care Model (OCM) represented one of the most advanced efforts yet to migrate health care delivery from fee-for-service to fee-for-value. Practices representing nearly...

...

12/13/2018

Journal of Clinical Pathways

Perspectives

Bundled Payments: A Rising Tide for Clinical Pathways

12/13/2018

Joshua M Liao, MD, MSc, FACP

Abstract: As a value-based payment model, bundled payments represent a key component of the ongoing nationwide shift toward value-based care. The Centers for Medicare & Medicaid Services (CMS) has led the...

...

12/13/2018

Journal of Clinical Pathways

Research Reports

Cancer Patient Perspectives on the Use of Clinical Pathways and Shared Decision-Making in Cancer Care

11/18/2018

Elizabeth F Franklin, MSW, LGSW, ACSW

Helen M Nichols, PhD, MSW

Ellyn Charap, MS

Joanne S Buzaglo, PhD

Shauna McManus, BS

Linda House, MSM, BSN, RN

Abstract: The United States has one of the most expensive heath care systems in the world, and the costs of cancer care are rising faster than costs in other medical fields. Value-based care is being implemented in...

...

11/18/2018

Journal of Clinical Pathways

Perspectives

Lessons From Effective Value-Based Care Models in Hematopoietic Stem Cell Transplantation

11/16/2018

James Gajewski, MD, MACP

Abstract: Patient-centered medical homes (PCMHs) have been designed to offer coordinated care delivery across the entire spectrum of care, aiming to provide optimal care for patients given their individual...

...

11/16/2018

Journal of Clinical Pathways

Research Reports

Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility

10/15/2018

Michael Kuehn, RPh

Jay Galli

Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...

...

10/15/2018

Journal of Clinical Pathways

From the Field

Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting

10/15/2018

Sandy Smith, RN, MSN, AOCN

James Essell, MD

Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...

...

10/15/2018

Journal of Clinical Pathways

Perspectives

The Future of Patients as the Audience for Pathways Rather Than Providers

09/13/2018

Guy Wood-Gush, MBBS, MBA

Vivek Patkar, MBBS, MRCS, FEBS

Abstract: Due to technologic and societal shifts, it seems clear that patients will be much more involved in their care going forward. Health care providers and decision-makers should consider these shifting...

...

09/13/2018

Journal of Clinical Pathways

Research Reports

Community Oncologists` Perception and Acceptance of Biosimilars in Oncology

09/13/2018

Chadi Nabhan, MD, MBA, FACP

Yolaine Jeune-Smith, PhD

Amy Valley, PharmD

Bruce A Feinberg, DO

Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...

...

09/13/2018

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products